Anaplastic Large Cell Lymphoma - 61 Studies Found
| Completed |
: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma : Large Cell Lymphoma : 2004-12-10 : Drug: SGN-30 |
| Completed |
: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas : Anaplastic Large Cell Lymphoma, ALK-Positive : 2015-04-03 : Drug: crizotinib |
| Withdrawn |
: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma : Lymphoma, Large-Cell : 2006-03-01 : Drug: MDX-060 |
| Active, not recruiting |
: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma :
|
| Completed |
: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma :
: 2009-03-19 : Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
| Completed |
: Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma : Lymphoma : 1999-11-01 : Biological: monoclonal antibody HeFi-1 |
| Recruiting |
: AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma :
|
| Active, not recruiting |
: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas :
: |
| Recruiting |
: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) : Lymphoma : 2014-06-11 : Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose |
| Completed |
: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas : Non-Hodgkin Lymphoma : 2014-10-05 : Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |